Symbiotix Biotherapies, Inc. is venture-backed microbiome company founded on the basis of over two decades of research at Harvard Medical School/Brigham & Women’s Hospital, California Institute of Technology and Dartmouth College. As one of the pioneers of the microbiome field, our company is developing a novel class of regulatory T cell (Treg) therapeutics based on molecules derived from the human microbiome. Symbiotix is dedicated to delivering first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases.